Fractyl Health, Inc. (NASDAQ:GUTS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $5.12.

Several equities research analysts recently weighed in on GUTS shares. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research note on Thursday, June 4th. Craig Hallum began coverage on shares of Fractyl Health in a research note on Wednesday, July 1st. They set a “buy” rating and a $4.00 target price for the company. Weiss Ratings upgraded Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Finally, Wall Street Zen lowered Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th.

Fractyl Health Stock Performance

Shares of Fractyl Health stock opened at $0.78 on Monday. The stock has a market capitalization of $124.16 million, a price-to-earnings ratio of -0.89 and a beta of 2.32. The company has a debt-to-equity ratio of 1.41, a current ratio of 3.15 and a quick ratio of 3.15. The business has a 50-day moving average of $0.76 and a 200 day moving average of $0.65. Fractyl Health has a 12 month low of $0.38 and a 12 month high of $2.44.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. As a group, sell-side analysts forecast that Fractyl Health will post -0.53 earnings per share for the current year.

Insiders Place Their Bets

In other Fractyl Health news, Director William Bradley acquired 68,493 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the completion of the purchase, the director owned 84,622 shares in the company, valued at $61,774.06. This trade represents a 424.66% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ian Sheffield bought 35,000 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, with a total value of $25,550.00. Following the purchase, the director directly owned 35,000 shares of the company’s stock, valued at approximately $25,550. This trade represents a ? increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 171,493 shares of company stock worth $127,150 over the last ninety days. Corporate insiders own 8.52% of the company’s stock.

Institutional Trading of Fractyl Health

Several hedge funds and other institutional investors have recently made changes to their positions in GUTS. Sanctuary Advisors LLC purchased a new position in Fractyl Health during the second quarter worth about $26,000. Jane Street Group LLC purchased a new position in shares of Fractyl Health during the 2nd quarter worth approximately $31,000. Accredited Investors Inc. acquired a new stake in shares of Fractyl Health in the 1st quarter valued at approximately $46,000. Scientech Research LLC acquired a new stake in shares of Fractyl Health in the 3rd quarter valued at approximately $49,000. Finally, FNY Investment Advisers LLC boosted its stake in shares of Fractyl Health by 84.3% in the second quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock valued at $51,000 after buying an additional 29,920 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.